EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
RF Dong, ML Zhu, MM Liu, YT Xu, LL Yuan… - Pharmacological …, 2021 - Elsevier
With the development of precision medicine, molecular targeted therapy has been widely
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …
[HTML][HTML] Targeted therapies in development for non-small cell lung cancer
T Reungwetwattana, GK Dy - Journal of carcinogenesis, 2013 - ncbi.nlm.nih.gov
The iterative discovery in various malignancies during the past decades that a number of
aberrant tumorigenic processes and signal transduction pathways are mediated by …
aberrant tumorigenic processes and signal transduction pathways are mediated by …
Krukovine suppresses KRAS-mutated lung cancer cell growth and proliferation by inhibiting the RAF-ERK pathway and inactivating AKT pathway
H Lai, Y Wang, F Duan, Y Li, Z Jiang, L Luo… - Frontiers in …, 2018 - frontiersin.org
Oncogenic activation of the KRAS gene via point mutations occurs in 20–30% of patients
with non-small cell lung cancer (NSCLC). The RAS-RAF-ERK and RAS-PI3K-AKT pathways …
with non-small cell lung cancer (NSCLC). The RAS-RAF-ERK and RAS-PI3K-AKT pathways …
Prevalence, Clinicopathologic Characteristics, and Molecular Associations of EGFR Exon 20 Insertion Mutations in East Asian Patients with Lung Adenocarcinoma
Purpose To define the prevalence, clinicopathologic characteristics and molecular
associations of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in East …
associations of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in East …
Drug combinatorial therapies for the treatment of KRAS mutated lung cancers
H He, C Xu, Z Cheng, X Qian… - Current Topics in …, 2019 - ingentaconnect.com
KRAS is the most common oncogene to be mutated in lung cancer, and therapeutics directly
targeting KRAS have proven to be challenging. The mutations of KRAS are associated with …
targeting KRAS have proven to be challenging. The mutations of KRAS are associated with …
[HTML][HTML] A novel insertion mutation on exon 20 of epidermal growth factor receptor, conferring resistance to erlotinib
NA Khan, S Mirshahidi, HR Mirshahidi - Case reports in oncology, 2014 - karger.com
The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein tyrosine
kinase receptor. The small-molecule tyrosine kinase receptor inhibitors (TKIs) are in clinical …
kinase receptor. The small-molecule tyrosine kinase receptor inhibitors (TKIs) are in clinical …